Outcomes assessed in trials of gout and accordance with OMERACT-proposed domains: A systematic literature review

Rheumatology (United Kingdom)

Volumn 54, Issue 6, 2015, Pages 981-993

  Araújo, Filipe ^a,b   Cordeiro, Inês ^c   Ramiro, Sofia ^c,d   Falzon, Louise ^e   Branco, Jaime C ^a,f   Buchbinder, Rachelle ^g,h  

^a HOSPITAL EGAS MONIZ   (Portugal)

^b INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^c HOSPITAL GARCIA DE ORTA   (Portugal)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

^e Och Spine at New York Presbyterian Hospitals   (United States)

^f NOVA MEDICAL SCHOOL   (Portugal)

^g CABRINI HOSPITAL   (Australia)

^h MONASH UNIVERSITY   (Australia)

Author keywords

Gout; Outcomes research; Patient perspective

Indexed keywords

ALLOPURINOL; FEBUXOSTAT; NONSTEROID ANTIINFLAMMATORY AGENT; URATE; URICOSURIC AGENT;

ALTERNATIVE MEDICINE; ARTICLE; GOUT; HUMAN; INFLAMMATION; OUTCOME ASSESSMENT; OUTCOMES RESEARCH; PAIN; PAIN ASSESSMENT; PATIENT SAFETY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; SYSTEMATIC REVIEW; URIC ACID BLOOD LEVEL;

EID: 84938507135     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keu424     Document Type: Article

References (86)

1. Tugwell P, Boers M. OMERACT Conference on Outcome Measures in Rheumatoid Arthritis Clinical Trials: Introduction. J Rheumatol 1993;20:528-30.
2. Schumacher R, Edwards L, Perez-Ruiz F et al. Outcome measures for acute and chronic gout. J Rheumatol 2005; 32:2452-5.
3. Schumacher R, Taylor W, Edwards L et al. Outcome domains for studies of acute and chronic gout. J Rheumatol 2009;36:2342-5.
4. Grainger R, Taylor WJ, Dalbeth N et al. Progress in measurement instruments for acute and chronic gout studies. J Rheumatol 2009;36:2346-55.
5. Taylor W, Schumacher R, Baraf H et al. A modified Delphi exercise to determine the extent of consensus with OMERACT outcome domains for studies of acute and chronic gout. Ann Rheum Dis 2008;67:888-91.
6. Schumacher R, Taylor W, Joseph-Ridge N et al. Outcome evaluations in gout. J Rheumatol 2007;34:1381-5.
7. Tugwell P, Boers M, Brooks P et al. OMERACT: An international initiative to improve outcome measurement in rheumatology. Trials 2007;8:38.
8. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. www.cochranehandbook. org (7 October 2014, date last accessed).
9. Sackett D, Richardson WS, Rosenberg W et al. Evidencebased medicine: how to practice and teach EBM. London: Churchill Livingstone, 1997.
10. Ahern MJ, Reid C, Gordon TP et al. Does colchicine work? The results of the first controlled study in acute gout. Aust N Z J Med 1987;17:301-4.
11. Alloway J, Moriarty M, Hoogland Y et al. Comparison of triamcinolone acetonide with indomethacin in the treatment of acute gouty arthritis. J Rheumatol 1993;20: 111-3.
12. Altman RD, Honig S, Levin JM, Lightfoot RW. Ketoprofen versus indomethacin in patients with acute gouty arthritis: a multicenter, double blind comparative study. J Rheumatol 1988;15:1422-6.
13. Axelrod D, Preston S. Comparison of parenteral adrenocorticotropic hormone with oral indomethacin in the treatment of acute gout. Arthritis Rheum 1988;31:803-5.
14. Butler RC, Goddard DH, Higgens CS et al. Double-blind trial of flurbiprofen and phenylbutazone in acute gouty arthritis. Br J Clin Pharmacol 1985;20:511-3.
15. Cheng T-T, Lai H-M, Chiu C-K et al. A single-blind, randomized, controlled trial to assess the efficacy and tolerability of rofecoxib, diclofenac sodium, and meloxicam in patients with acute gouty arthritis. Clin Ther 2004;26: 399-406.
16. Chou CT, Kuo SC. The anti-inflammatory and anti-hyperuricemic effects ofChinese herbal formulaDanggui-Nian-Tong-Tang on acute gouty arthritis: a comparative studywith indomethacin and allopurinol. Am J Chin Med 1995;23:261-71.
17. Garcia de la Torre I. A comparative, double-blind, parallel study with tenoxicam vs placebo in acute gouty arthritis. Invest Med Int 1987;14:92-7.
18. Douglas G, Thompson M. A comparison of phenylbutazone and flufenamic acid in the treatment of acute gout. Ann Phys Med 1970;10:275-80.
19. Eberl R, Dunky A. Meclofenamate sodium in the treatment of acute gout. Results of a double-blind study. Arzneimittelforschung 1983;33:641-3.
20. Fraser R, Harvard Davis R, Walker F. Comparative trial of azapropazone and indomethacin plus allopurinol in acute gout and hyperuricemia. J R Coll Gen Pract 1987;37: 409-11.
21. Janssens HJ, Janssen M, van de Lisdonk EH et al. Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial. Lancet 2008;371:1854-60.
22. Ji W, Zhu X, Tan W et al. Effects of Rebixiao granules on blood uric acid in patients with repeatedly attacking acute gouty arthritis. Chin J Integr Med 2005;11:15-21.
23. Klumb EM, Pinheiro GRC, Ferrari A et al. O tratamento da crise aguda de gota. Estudo duplo-cego, randômico, comparativo entre nimesulide e indometacina. Rev Bras Med 1996;53:540-6.
24. Lederman R. A double-blind comparison of Etodolac (Lodine) and high doses of naproxen in the treatment of acute gout. Adv Ther 1990;7:344-54.
25. Lomen PL, Turner LF, Lamborn KR et al. Flurbiprofen in the treatment of acute gout. A comparison with indomethacin. Am J Med 1986;80:134-9.
26. Maccagno A, Di Giorgio E, Romanowicz A. Effectiveness of etodolac ('Lodine') compared with naproxen in patients with acute gout. Curr Med Res Opin 1991;12:423-9.
27. Man CY, Cheung ITF, Cameron PA, Rainer TH. Comparison of oral prednisolone/paracetamol and oral indomethacin/paracetamol combination therapy in the treatment of acute goutlike arthritis: a double-blind, randomized, controlled trial. Ann Emerg Med 2007;49:670-7.
28. Marcolongo R, Lucchese M, Caruso I et al. Intravenous indoprofen for prompt relief of acute gout: a regimenfinding study. J Int Med Res 1980;8:326-32.
29. Qiu R, Shen R, Lin D et al. Treatment of 60 cases of gouty arthritis with modified Simiao tang. J Tradit Chin Med 2008;28:94-7.
30. Reardon JA, Stockman A, Darlington LG et al. Doubleblind trial of feprazone and phenylbutazone in acute gout. Curr Med Res Opin 1980;6:445-8.
31. Rubin BR, Burton R, Navarra S et al. Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial. Arthritis Rheum 2004;50:598-606.
32. Schlesinger N, Detry MA, Holland BK et al. Local ice therapy during bouts of acute gouty arthritis. J Rheumatol 2002;29:331-4.
33. Schlesinger N, Meulemeester MD, Pikhlak A et al. Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat gouty arthritis by suppressing inflammation: results of a randomized dose-ranging study. Arthritis Res Ther 2011;13:1-13.
34. Schumacher HR Jr, Boice JA, Daikh DI et al. Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis. BMJ 2002;324:1488-92.
35. Shrestha M, Morgan DL, Moreden JM et al. Randomized double-blind comparison of the analgesic efficacy of intramuscular ketorolac and oral indomethacin in the treatment of acute gouty arthritis. Ann Emerg Med 1995; 26:682-6.
36. Shi X, Li GC, Qian ZX et al. Randomized and controlled clinical study of modified prescriptions of Simiao-Pill in the treatment of acute gouty arthritis. Chin J Integr Med 2008; 14:17-22.
37. Siegel LB, Alloway JA, Nashel DJ. Comparison of adrenocorticotropic hormone and triamcinolone acetonide in the treatment of acute gouty arthritis. J Rheumatol 1994; 21:1325-7.
38. Smyth CJ, Percy JS. Comparison of indomethacin and phenylbutazone in acute gout. Ann Rheum Dis 1973;32: 351-3.
39. So A, De Meulemeester M, Pikhlak A et al. Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: results of a multicenter, phase II, dose-ranging study. Arthritis Rheum 2010;62:3064-76.
40. Sturge RA, Scott JT, Hamilton EB et al. Multicentre trial of naproxen and phenylbutazone in acute gout. Ann Rheum Dis 1977;36:80-2.
41. Terkeltaub RA, Furst DE, Bennett K et al. High versus low dosing of oral colchicine for early acute gout flare: Twentyfour-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dosecomparison colchicine study. Arthritis Rheum 2010;62: 1060-8.
42. Tumrasvin T, Deesomchok U. Piroxicam in treatment of acute gout high dose versus low dose. J Med Assoc Thai 1985;68:111-6.
43. Valdes EF. Use of tenoxicam in patients with acute gouty arthritis. Eur J Rheumatol Inflamm 1987;9:133-6.
44. Weiner GI, White SR, Weitzner RI et al. Double-blind study of fenoprofen versus phenylbutazone in acute gouty arthritis. Arthritis Rheum 1979;22:425-6.
45. Willburger RE, Mysler E, Derbot J et al. Lumiracoxib 400 mg once daily is comparable to indomethacin 50 mg three times daily for the treatment of acute flares of gout. Rheumatology 2007;46:1126-32.
46. Zou R, Zhang H, Zhang T. Comparative study on treatment of acute gouty arthritis by electroacupuncture with different frequency. Chin J Integr Med 2006;12:212-4.
47. Arroll B, Bennett M, Dalbeth N et al. More allopurinol is needed to get gout patients < 0.36 mmol/l: a gout audit in the form of a before-after trial. J Prim Health Care 2009;1: 315-8.
48. Becker MA, Schumacher HR Jr, Wortmann RL et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005;353: 2450-61.
49. Becker MA, Schumacher HR Jr, Wortmann RL et al. Febuxostat, a novel non-purine selective inhibitor of xanthine oxidase: a twenty-eight day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum 2005;52:916-23.
50. Becker MA, Schumacher HR, MacDonald PA et al. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol 2009;36:1273-82.
51. Borstad GC, Bryant LR, Abel M et al. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol 2004;31:2429-32.
52. Gibson T, Rodgers V, Potter C et al. Allopurinol treatment and its effect on renal function in gout: a controlled study. Ann Rheum Dis 1982;41:59-65.
53. Karimzadeh H, Nazari J, Mottaghi P et al. Different duration of colchicine for preventing recurrence of gouty arthritis. J Res Med Sci 2006;11:104-7.
54. Muller EO, Schall R, Groenewoud G et al. The effect of benzbromarone on allopurinol/oxypurinol kinetics in patients with gout. Eur J Clin Pharmacol 1993;44: 69-72.
55. Ohue T, Yamamoto T, Hada T et al. Effects of allopurinol and benzbromarone on renal clearance of creatinine and uric acid in gouty patients. Jpn J Rheumatol 1991;3: 21-7.
56. Perez-Ruiz F, Calabozo M, Fernandez-Lopez MJ et al. Treatment of chronic gout in patients with renal function impairment: an open, randomized, actively controlled study. J Clin Rheumatol 1999;5:49-55.
57. Paulus HE, Schlosstein LH, Godfrey R et al. Prophylactic colchicine therapy of intercritical gout. A placebo-controlled study of probenecid-treated patients. Arthritis Rheum 1974;17:609-14.
58. Porcelli B, Vannoni D, Leoncini R et al. Free oxypurines in plasma and urine of gout patients before and after a purine-free diet. Adv Exp Med Biol 1994;370:47-52.
59. Reinders MK, Haagsma C, Jansen T et al. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout. Ann Rheum Dis 2009;68:892-7.
60. Reinders MK, van Roon EN, Jansen T et al. Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol. Ann Rheum Dis 2009;68:51-6.
61. Rodnan G, Robin JA, Tolchin S et al. Allopurinol and gouty hyperuricaemia: efficacy of a single daily dose. JAMA 1975;231:1143-7.
62. Schumacher HR Jr, Becker MA, Wortmann R et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel group trial. Arthritis Rheum 2008;59:1540-8.
63. Schumacher R, Sundy J, Terkeltaub R et al. Rilonacept (interleukin-1 trap) in the prevention of acute gout flares during initiation of urate-lowering therapy. Arthritis Rheum 2012;64:876-84.
64. Scott JT. Comparison of allopurinol and probenecid. Ann Rheum Dis 1966;25:623-6.
65. Sundy JS, Baraf HSB, Yood R et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA 2011;306: 711-20.
66. Sundy J, Becker M, Baraf H et al. Reduction of plasma urate levels following treatment with multiple doses of pegloticase in patients with treatment-failure gout. Arthritis Rheum 2008;58:2889-91.
67. Stamp LK, O'Donnell JL, Dalbeth N et al. Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. Arthritis Rheum 2011;63: 412-21.
68. Takahashi S, Moriwaki Y, Yamamoto T et al. Effects of combination treatment using anti-hyperuricaemic agents with fenofibrate and/or losartan on uric acid metabolism. Ann Rheum Dis 2003;62:572-5.
69. Tsutsumi Z, Moriwaki Y, Takahashi S et al. Oxidized lowdensity lipoprotein autoantibodies in patients with primary gout: effect of urate-lowering therapy. Clin Chim Acta 2004;339:117-22.
70. Wang T, Bi Y, Huang G et al. Serum uric acid associates with the incidence of type 2 diabetes in a prospective cohort of middle-aged and elderly Chinese. Endocrine 2011;40:109-16.
71. Song E, Xiang Q, Ren K et al. Clinical effect and action mechanism of Weicao Capsule in treating gout. Chin J Integr Med 2008;14:103-6.
72. Taylor T, Mechella J, Larson R et al. Initiation of allopurinol at first medical contact for acute attacks of gout: a randomized clinical trial. Am J Med 2012;125: 1126-34.
73. Dalbeth N, Ames R, Gamble G et al. Effects of skim milk powder enriched with glycomacropeptide and G600 milk fat extract on frequency of gout flares: a proof-of-concept randomised controlled trial. Ann Rheum Dis 2012;71: 929-34.
74. Schumacher R, Evans R, Saag K et al. Rilonacept (Interleukin-1 Trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study. Arthritis Care Res 2012;64: 1462-70.
75. Schumacher R, Berger M, Li-Yu J et al. Efficacy and tolerability of celecoxib in the treatment of acute gouty arthritis: a randomized controlled trial. J Rheumatol 2012; 39:1859-66.
76. Sundy J, Ganson N, Kelly S et al. Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxydase in patients with refractory gout. Arthritis Rheum 2007;56: 1021-8.
77. Taylor W, Schumacher R, Singh J et al. Assessment of outcome in clinical trials of gout-a review of current measures. Rheumatology 2007;46: 1751-1756.
78. Clarke M. Standardising outcomes for clinical trials and systematic reviews. Trials 2007. Advance Access published 26 November 2007 doi: 10.1186/1745-6215-8-39.
79. Felson DT, Anderson JJ, Boers M et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum 1993;36:729-40.
80. van der Heijde D, van der Linden S, Dougados M et al. Ankylosing Spondylitis: plenary discussion and results of voting on selection of domains and some specific instruments. J Rheumatol 1999;26:1003-5.
81. van der Heijde D, van der Linden S, Bellamy N et al. Which domains should be included in a core set for endpoints in ankylosing spondylitis? Introduction to the Ankylosing Spondylitis Module of OMERACT IV. J Rheumatol 1999; 26:945-7.
82. van der Heijde D, Calin A, Dougados M et al. Selection of instruments in the core set for DC-ART, SMARD, Physical Therapy and Clinical Record Keeping in ankylosing spondylitis. Progress Report of the ASAS Working Group. J Rheumatol 1999;26:951-4.
83. European Medicines Agency. Concept paper on the need of the guideline on clinical investigation of medicinal products for the treatment of gout. 2012. http://www.ema. europa.eu/docs/en_GB/document_library/Scientific_ guideline/2012/06/WC500128670.pdf (10 June 2014, date last accessed).
84. Singh J, Taylor W, Simon L et al. Patient-reported outcomes in chronic gout: a report from OMERACT 10. J Rheumatol 2011;38:1452-61.
85. Chandratre P, Roddy E, Clarson L et al. Health-related quality of life in gout: a systematic review. Rheumatology 2013;52:2031-40.
86. Dalbeth N, Clark B, McQueen F et al. Validation of a radiological damage index in chronic gout. Arthritis Care Res 2007;57:1067-73.